Cited by 171Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Open access

Costa, Daniel B., Nguyen, Kim-Son H., Cho, Byoung C., Sequist, Lecia V., Jackman, David M., Riely, Gregory J., Yeap, Beow Y., Halmos, Balázs, Kim, Joo H., Jänne, Pasi A., Huberman, Mark S., Pao, William, Tenen, Daniel G., Kobayashi, Susumu·2008·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-08-1455PMC PMC2596582

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR) mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) invariably ensues. The T790M mutation occurs in 50% and MET amplification in 20% of TKI-resistant tumors. Other secondary mutations (D761Y and L747S) are rare. Our goal was to determine the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib. Experimental Design: Retrospective review of 18 EGFR mutated (exon 19 deletions, L858R, and L861Q) patients that were given gefitinib and subsequently erlotinib. Seven patients had tumor resampling after TKI therapy and were analyzed for secondary EGFR mutations and MET amplification. Results: Most patients (14 of 18) responded to gefitinib with median progression-free survival of 11 months (95% confidence interval, 4-16). After gefitinib resistance (de novo or acquired), 78% (14 of 18) of these patients displayed progressive disease while on erlotinib with progression-free survival of 2 months (95% confidence interval, 2-3). Six of 7 resampled patients acquired the T790M mutation, and 0 of 3 had MET amplification. Only 1 gefitinib-resistant patient with the acquired L858R-L747S EGFR, which in vitro is sensitive to achievable serum concentrations of erlotinib 150 mg/d, achieved a partial response to erlotinib. Conclusions: In EGFR mutated tumors resistant to gefitinib 250 mg/d, a switch to erlotinib 150 mg/d does not lead to responses in most patients. These findings are consistent with preclinical models, because the common mechanisms of TKI resistance (T790M and MET amplification) in vitro are not inhibited by clinically achievable doses of gefitinib or erlotinib. Alternative strategies to overcome TKI resistance must be evaluated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-1455

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Cancer Statistics, 2008
Jemal, A., Siegel, R. L., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,184
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation

Show all 67 references

Sorted by citations

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Self-citation
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571
Self-citation
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
Self-citation
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 393
Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Lin, J. J., Cardarella, S., Lydon, C., Dahlberg, S. E., Jackman, D. M., Janne, P. A., & Johnson, B. E. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.103 · Cited by 358
Self-citation
Molecular chess? Hallmarks of anti-cancer drug resistance
Cree, I. A., & Charlton, P. (2017) · BMC Cancer · doi:10.1186/s12885-016-2999-1 · Cited by 353
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng, C., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Antonio Lopez-beltran, B., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 249
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 217
Self-citation
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., Isobe, H., Harada, M., Ishii, Y., Gemma, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000048 · Cited by 204
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
Dong, R., Zhu, M., Liu, M., Xu, Y., Yuan, L.-L., Bian, J., Xia, Y., & Kong, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105583 · Cited by 211
The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations
Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176
Self-citation
T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
Ma, C., Wei, S., & Song, Y. J. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.02 · Cited by 158
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
VanderLaan, P. A., Yamaguchi, N., Folch, E. E., Boucher, D. H., Kent, M. S., Gangadharan, S. P., Majid, A., Goldstein, M. A., Huberman, M. S., Kocher, O. N., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.013 · Cited by 156
Self-citation
The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies
Patterson, S. E., Liu, R., Statz, C. M., Durkin, D., Lakshminarayana, A., & Mockus, S. M. (2016) · Human Genomics · doi:10.1186/s40246-016-0061-7 · Cited by 140
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131
Self-citation
Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy
Al-Halabi, H., Sayegh, K., Digamurthy, S. R., Niemierko, A., Piotrowska, Z., Willers, H., & Sequist, L. V. D. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000648 · Cited by 121
Self-citation
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 121
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112
Self-citation
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer
Lee, Y. J., Choi, H. J., Kim, S. I., Chang, J., Moon, J. W., Park, I. K., Kim, J.-H., & Cho, B. C. (2010) · Cancer · doi:10.1002/cncr.24877 · Cited by 106
Self-citation
Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
Xu, L., Kikuchi, E., Xu, C., Ebi, H., Ercan, D., Cheng, K. A., Padera, R. F., Engelman, J. A., Janne, P. A., Shapiro, G. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3720 · Cited by 106
Self-citation
Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein
Zhou, W., Zhang, X., Cheng, C., Wang, F., Wang, X., Liang, Y.-J., To, K. K. W., Wang, Z., Huang, H., & Fu, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01849.x · Cited by 100
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy
Yeh, P. G., Chen, H., Andrews, J., Naser, R., Pao, W. J., & Horn, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1894 · Cited by 98
Self-citation
Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Zhang, X., Liu, W., Jiang, H.-L., & Mao, B. (2018) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x18500490 · Cited by 85
Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
Yeo, W.-L., Riely, G. J., Yeap, B. Y., Lau, M. W., Warner, J. L., Bodio, K., Huberman, M. S., Kris, M. G., Tenen, D. G., Pao, W. J., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dd1386 · Cited by 82
Self-citation
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
Rolfo, C. D., Giovannetti, E., Hong, D. S., Bivona, T. G., Raez, L. E., Bronte, G., Buffoni, L., Reguart, N., Santos, E. S., Germonpré, P. R., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.05.009 · Cited by 80
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11881 · Cited by 79
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
Bronte, G., Rolfo, C. D., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., Castiglia, M., Rizzo, S., Vullo, F. L., Fiorentino, E., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.003 · Cited by 78
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
Nakamura, T., Sueoka‐Aragane, N., Iwanaga, K., Sato, A., Komiya, K., Abe, T., Ureshino, N., Hayashi, S., Hosomi, T., Hirai, M., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822956e8 · Cited by 74
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
Tanaka, A., Sueoka‐Aragane, N., Nakamura, T., Takeda, Y., Mitsuoka, M., Yamasaki, F., Hayashi, S., Sueoka, E., & Kimura, S. H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.004 · Cited by 67
Genetically informed lung cancer medicine
Pao, W. J., Iafrate, A. J., & Su, Z. (2010) · The Journal of Pathology · doi:10.1002/path.2788 · Cited by 69
Self-citation
EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
Brugger, W., & Thomas, M. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.014 · Cited by 66
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
Kaira, K., Naito, T., Takahashi, T., Ayabe, E., Shimoyama, R., Kaira, R., Ono, A., Igawa, S., Shukuya, T., Murakami, H., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.006 · Cited by 61
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Tomizawa, Y., Fujita, Y., Tamura, A., Shirai, M., Shibata, S., Kawabata, T., Shibayama, T., Fukai, S., Kawahra, M., & Saito, R. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.025 · Cited by 59
Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer
Ali, Z., Vildevall, M., Rodriguez, G. V., Tandiono, D., Vamvakaris, I. N., Evangelou, G., Lolas, G., Syrigos, K. N., Villanueva, A., Wick, M. J., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02280-x · Cited by 57
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice
Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Boucher, D. H., Canepa, H. M., Kent, M. S., Gangadharan, S. P., Majid, A., Kocher, O. N., Goldstein, M. A., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.013 · Cited by 56
Self-citation
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Neal, J. W., & Nguyen, K.-S. H. (2012) · Biologics · doi:10.2147/btt.s26558 · Cited by 53
Self-citation
Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway
Yang, L., Li, J., Xu, L., Lin, S., Xiang, Y., Dai, X., Liang, G., Huang, X., Zhu, J., & Zhao, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s171517 · Cited by 52
Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations
Gaughan, E. M., Cryer, S. K., Yeap, B. Y., Jackman, D. M., & Costa, D. B. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.002 · Cited by 49
Self-citation
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
Rosell, R., Viteri, S., Molina‐Vila, M. Á., Benlloch, S., & Tarón, M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833500d2 · Cited by 45
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Asahina, H., Oizumi, S., Inoue, A., Kinoshita, I., Ishida, T., Fujita, Y., Sukoh, N., Harada, M., Maemondo, M., Saijo, Y., et al. (2010) · Oncology · doi:10.1159/000326488 · Cited by 46
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Pilotto, S., Rossi, A., Vavalà, T., Follador, A., Tiseo, M., Galetta, D., Morabito, A., Di Maio, M., Martelli, O., Caffo, O., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.016 · Cited by 46
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
Liang, S., Ko, J., Yang, J. C., & Shih, J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.019 · Cited by 46
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45
Molecular testing in lung cancer in the era of precision medicine.
Popper, H., Ryška, A., Tı́már, J., & Olszewski, W. T. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.10.01 · Cited by 44
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
Conforti, F., Catania, C., Toffalorio, F., Duca, M., Spitaleri, G., Barberis, M. C. P., Noberasco, C., Delmonte, A., Santarpía, M., Lazzari, C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.019 · Cited by 43
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Hussain, S., Mursal, M., Verma, G., Hasan, S. S., & Khan, M. F. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176484 · Cited by 41
Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors
Verma, G., Khan, M. F., Akhtar, W., Alam, M. M., Akhter, M., Alam, O., Hasan, S. S., & Shaquiquzzaman, M. (2016) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2016.09.019 · Cited by 41
Biomarkers in oncology drug development
Hodgson, D., Whittaker, R. D., Herath, A., Amakye, D. D., & Clack, G. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.12.002 · Cited by 39
Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
Fang, Y., Yang, Y., Hsieh, M., Hung, M., & Lin, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s222278 · Cited by 39
Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity inKRASwild-type tumors
Berry, W., Algar, E. M., Kumar, B., Desmond, C., Swan, M. P., Jenkins, B. J., & Croagh, D. G. (2017) · International Journal of Cancer · doi:10.1002/ijc.30648 · Cited by 40
Lung Cancer in Never Smokers
Yang, P. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1272865 · Cited by 38
Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future
Cagle, P. T., & Allen, T. C. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0508-ra · Cited by 36
Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases
Yamaguchi, F., Fukuchi, K., YAMAZAKI, Y., Takayasu, H., Tazawa, S., Tateno, H., Katô, E., Wakabayashi, A., FUJIMORI, M., Iwasaki, T., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1705 · Cited by 36
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Wang, Y., Ning, W., Li, J., & Huang, J. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.05.95 · Cited by 36
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
Landi, L. M., Tiseo, M., Chiari, R., Ricciardi, S., Rossi, E., Galetta, D., Novello, S., Milella, M., D’Incecco, A., Minuti, G., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.07.002 · Cited by 35
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
Sentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 34
Self-citation
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology
Lee, S. H., & Jang, H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0394 · Cited by 39
EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)
Tian, Z., Cen, L., Feng, W., Dong, J., Huang, Y., Han, Y., Wang, Z., Deng, J., & Jiang, Y. (2025) · Oncology Letters · doi:10.3892/ol.2025.15121 · Cited by 34
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
Takeda, M., Okamoto, I., Tsurutani, J., Oiso, N., Kawada, A., & Nakagawa, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys042 · Cited by 32
Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy
Yamaguchi, F., Kugawa, S., Tateno, H., Kokubu, F., & Fukuchi, K. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.014 · Cited by 33
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Wong, M. K., Lo, A. I., LAM, B. K., Lam, W. K., Ip, M., & Ho, J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1107-5 · Cited by 29
Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors
Iwama, E., Sakai, K., Hidaka, N., Inoue, K., Fujii, A., Nakagaki, N., Ota, K., Toyozawa, R., Azuma, K., Nakatomi, K., et al. (2019) · Cancer · doi:10.1002/cncr.32481 · Cited by 28
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
Asami, K. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.646 · Cited by 25
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu, G., Xie, X., Sun, D., Geng, J., Fu, F., Zhang, L., & Wang, H. (2015) · PubMed Central · Cited by 26
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
Zhou, Z.-T., Xu, X., Wei, Q., Lu, M., Wang, J., & Cai-hong, W. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0973-1 · Cited by 25
Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants
Chung, B. M. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.806 · Cited by 25
Subsequent Treatment Choices for Patients with Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer: Restore after a Drug Holiday or Switch to another EGFR-TKI?
Song, T., Yu, W., & Wu, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.1.205 · Cited by 25
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Lee, J. C., Jang, S. H., Lee, K. Y., & Kim, Y. (2013) · Cancer Research and Treatment · doi:10.4143/crt.2013.45.2.79 · Cited by 24
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Koh, S., Ross, K. N., Isakoff, S. J., Melkonjan, N., He, L., Matissek, K. J., Schultz, A., Mayer, E. L., Traina, T. A., Carey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0714 · Cited by 23
Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug
Lee, Y., Kim, H. Y., Lee, S.-H., Lim, K. Y., Lee, G. K., Yun, T., Han, J., Kim, H. T., & Lee, J. S. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.11.008 · Cited by 23
Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer
Cohen, V., Agulnik, J. S., Ang, C., Kasymjanova, G., Batist, G., Small, D. I., Brandao, G., Chong, G., & Miller, W. H. (2010) · Cancer · doi:10.1002/cncr.25214 · Cited by 22
Omics and Computational Modeling Approaches for the Effective Treatment of Drug-Resistant Cancer Cells
Jung, H. D., Sung, Y. J., & Kim, H. U. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.742902 · Cited by 22
Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development
Mahalingam, D., Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.03.001 · Cited by 21
Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
Kim, H. S., Sung, J. S., Yang, S.-J., Kwon, N., Jin, L., Kim, S. T., Park, K. H., Shin, S. W., Kim, H. K., Kang, J. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081975 · Cited by 20
Self-citation
Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Ohue, Y., Kurose, K., Mizote, Y., Matsumoto, H., Nishio, Y., Isobe, M., Fukuda, M., Uenaka, A., Oka, M., & Nakayama, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0742 · Cited by 20
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer
de Figueiredo‐Pontes, L. L., Wong, D., Tin, V. P., Chung, L., Yasuda, H., Yamaguchi, N., Nakayama, S., Janne, P. A., Wong, M. P., Kobayashi, S. S., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000050 · Cited by 19
Self-citation
EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression
Assche, K. V., Ferdinande, L., Lievens, Y. N., Vandecasteele, K., & Surmont, V. F. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00350 · Cited by 19
Ganoderma triterpenoids attenuate tumour angiogenesis in lung cancer tumour-bearing nude mice
Liu, W., Yuan, R., Hou, A., Tan, S., Liu, X. Z., Tan, P., Huang, X., & Wang, J. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1839111 · Cited by 18
Neoadjuvant Erlotinib and Surgical Resection of a Stage IIIA Papillary Adenocarcinoma of the Lung with an L861Q Activating EGFR Mutation
Ong, M., Kwan, K. F., Kamel‐Reid, S., & Vincent, M. D. (2012) · Current Oncology · doi:10.3747/co.19.908 · Cited by 18
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
Lee, V. H.-F., Leung, D. K. C., Choy, T., Lam, K. O., Lam, P. K. L., Leung, T., & Kwong, D. L. �. (2016) · BMC Cancer · doi:10.1186/s12885-016-2201-9 · Cited by 18
How and when to use genetic markers for nonsmall cell lung cancer
Lazarus, D. R., & Ost, D. E. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328362075c · Cited by 17
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
Plönes, T., Engel-Riedel, W., Stoelben, E., Limmroth, C., Schildgen, O., & Schildgen, V. (2016) · Journal of Personalized Medicine · doi:10.3390/jpm6010003 · Cited by 17
Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
Califano, R., Romanidou, O., Mountzios, G., Landi, L. M., Cappuzzo, F., & Blackhall, F. H. (2016) · Drugs · doi:10.1007/s40265-016-0578-z · Cited by 16
Recent Advances in Enzyme Inhibition: A Pharmacological Review
Singh, K., Bhushan, B., Mittal, N., Kushwaha, A., Raikwar, C. K., Sharma, A. K., Chanchal, D. K., Kumar, S., & Agrawal, M. (2023) · Current Enzyme Inhibition · doi:10.2174/0115734080271639231030093152 · Cited by 18
Biomarkers in lung oncology
Rosell, R., Vergnenégre, A., Liu, B., Cobo, M., Massutí, B., Wei, J., Molina‐Vila, M. Á., Costa, C., Queralt, C., & Tarón, M. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.05.003 · Cited by 16
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+release
Lamoral‐Theys, D., Wauthoz, N., Heffeter, P., Mathieu, V., Jungwirth, U., Lefranc, F., Nève, J., Dubois, J., Dufrasne, F., Amighi, K., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01403.x · Cited by 15
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis
Azad, T. D., Nanjo, S., Jin, M. C., Chabon, J. J., Kurtz, D. M., Chaudhuri, A. A., Connolly, I. D., Hui, A. B., Liu, C. L., Merriott, D. J., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00582-1 · Cited by 15
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
Cho, K. M., Keam, B., Kim, T. M., Lee, S., Kim, D., & Heo, D. S. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.891 · Cited by 14
Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Singh, N. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.858 · Cited by 13
Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung
Mohamad, N., Jayalakshmi, P., Rhodes, A., Liam, C. K., Tan, J.-L., Yousoof, S. B. M., & Rajadurai, P. (2017) · British Journal of Biomedical Science · doi:10.1080/09674845.2017.1331520 · Cited by 13
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure
Guan, Y., Zhao, H., Meng, J., Yan, X., & Jiao, S. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.002 · Cited by 12
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis
MITSUYA, S., Tsuruoka, K., Kanaoka, K., Funamoto, T., Tsuji, H., Matsunaga, N., Nakamura, T., Tamura, Y., Imanishi, M., IKEDA, S., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15331 · Cited by 13
Value-added anticancer reactivity of sub-5 nm Ag-drug nanoparticles derived from organosilver(I) MOF
Song, C., Zhang, J., Qiu, Y., Jin, H.-P., Zhang, H., Liu, S., Liu, H., Qiu, H., & Gao, G. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9376-7 · Cited by 12
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
Yang, C., Tsai, M., Hung, J., Tsai, Y., Lee, J., Chou, S., Liu, T., Shen, M., Huang, M., & Chong, I. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100169 · Cited by 11
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Song, Z., Yu, Y., Chen, Z., & Lu, S. (2011) · PubMed · Cited by 11

Authors: Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., Huberman, M. S., Pao, W., Tenen, D. G., & Kobayashi, S.
Affiliations: Beth Israel Deaconess Medical Center (US)
Yonsei University (KR)
Massachusetts General Hospital (US)
Harvard University (US)
Memorial Sloan Kettering Cancer Center (US)
6Case Western Reserve University, Cleveland, Ohio
3Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts;
ORCID: Costa, Daniel B.
Cho, Byoung C.
Sequist, Lecia V.
Riely, Gregory J.
Yeap, Beow Y.
Pao, William
Tenen, Daniel G.
Kobayashi, Susumu
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2008-11-01
Volume: 14
Issue: 21
Pages: 7060-7067
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-08-1455
PMC: PMC2596582
OpenAlex: W2154226624
Cited by: 171
References: 67
Citations by year: 2026: 1 · 2025: 11 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 9 · 2018: 4 · 2017: 6 · 2016: 14 · 2015: 10 · 2014: 15 · 2013: 18 · 2012: 24
FWCI: 11.32
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Pfizer
AstraZeneca
National Institutes of Health
Genentech
National Cancer Institute (2PA50-CA09057806, R01CA114465, P50CA090578, K99CA126026, P20CA090578)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: erlotinib, gefitinib, EGFR mutation, non-small cell lung cancer, tyrosine kinase inhibitor resistance, T790M mutation, MET amplification, exon 19 deletion, L858R, progression-free survival, drug dose comparison
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks